Galectin Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Galectin Therapeutics

15/08/2022 14:33

* Galectin Therapeutics Inc  GALT.OQ  reported a quarterly
adjusted loss of 16 cents​​ per share for the quarter ended in
June. The lone analyst forecast for the quarter was for a loss
of 19 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Galectin Therapeutics Inc's reported EPS for the quarter
was a
loss of 16 cents​.
    * The mean earnings estimate of analysts had fallen by
about 35.7%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Galectin Therapeutics Inc shares had risen by 58.0% this
quarter and held steady so far this year.
    * The company reported a quarterly loss of $9.68 million.
    * Wall Street's median 12-month price target for Galectin
Therapeutics Inc is $11.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data August 15
at 01:33 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2022      -0.19          -0.16          Beat
 Mar. 31 2022      -0.14          -0.17          Missed
 Dec. 31 2021      -0.19          -0.12          Beat
 Sep. 30 2021      -0.18          -0.14          Beat